ES3057685T3 - Treatment of liver, biliary tract and pancreatic disorders with defensins - Google Patents

Treatment of liver, biliary tract and pancreatic disorders with defensins

Info

Publication number
ES3057685T3
ES3057685T3 ES17727094T ES17727094T ES3057685T3 ES 3057685 T3 ES3057685 T3 ES 3057685T3 ES 17727094 T ES17727094 T ES 17727094T ES 17727094 T ES17727094 T ES 17727094T ES 3057685 T3 ES3057685 T3 ES 3057685T3
Authority
ES
Spain
Prior art keywords
defensin
fat
mammalian
hbd
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17727094T
Other languages
English (en)
Spanish (es)
Inventor
Peter Nordkild
Søren Kjaerulff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Defensin Therapeutics ApS
Original Assignee
Defensin Therapeutics ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defensin Therapeutics ApS filed Critical Defensin Therapeutics ApS
Application granted granted Critical
Publication of ES3057685T3 publication Critical patent/ES3057685T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17727094T 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders with defensins Active ES3057685T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670276 2016-04-29
DKPA201670484 2016-07-01
PCT/DK2017/050132 WO2017186250A1 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders

Publications (1)

Publication Number Publication Date
ES3057685T3 true ES3057685T3 (en) 2026-03-04

Family

ID=58992579

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17727094T Active ES3057685T3 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders with defensins

Country Status (13)

Country Link
US (1) US12076368B2 (https=)
EP (1) EP3448409B1 (https=)
JP (1) JP2019514908A (https=)
KR (1) KR102465341B1 (https=)
CN (1) CN109414474B (https=)
AU (1) AU2017258242B2 (https=)
BR (1) BR112018071972A2 (https=)
CA (1) CA3022497A1 (https=)
ES (1) ES3057685T3 (https=)
PL (1) PL3448409T3 (https=)
RU (1) RU2740913C2 (https=)
SG (1) SG11201809086YA (https=)
WO (1) WO2017186250A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
CN110279851A (zh) * 2019-07-05 2019-09-27 浙江大学 Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR102735773B1 (ko) * 2022-11-10 2024-11-27 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2487895A1 (en) 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US20100104529A1 (en) 2006-05-01 2010-04-29 England Robert L TNF-alpha VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-alpha
JP2009541287A (ja) * 2006-06-20 2009-11-26 リポペプチド・アクチエボラーグ 抗癌剤としてのカテリシジン抗菌タンパク質（ｈＣＡＰ１８）の使用
WO2008115390A2 (en) * 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
SG172709A1 (en) * 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
AP2011005537A0 (en) 2008-07-18 2011-02-28 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins.
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
US20110311601A1 (en) 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
DE102010040153A1 (de) 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
WO2013006692A2 (en) * 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
CN104971343B (zh) * 2015-07-13 2018-02-02 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063B (zh) * 2015-10-19 2019-10-01 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用
BR112018015170A2 (pt) 2016-01-26 2018-12-18 Defensin Therapeutics Aps métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1.
WO2017185549A1 (zh) * 2016-07-30 2017-11-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法2
CN114075585A (zh) * 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种β-烟酰胺单核苷酸的制备方法
CN112795606B (zh) * 2021-04-14 2021-07-27 深圳瑞德林生物技术有限公司 一种β-烟酰胺单核苷酸的酶催化合成方法
CN114107160B (zh) * 2021-12-27 2025-04-25 浙江英沃迪生物科技有限公司 一种烟酰胺核糖激酶基因工程菌及其应用

Also Published As

Publication number Publication date
PL3448409T3 (pl) 2026-02-23
EP3448409B1 (en) 2025-12-03
US12076368B2 (en) 2024-09-03
AU2017258242B2 (en) 2024-04-04
JP2019514908A (ja) 2019-06-06
RU2018141326A3 (https=) 2020-08-06
AU2017258242A1 (en) 2018-11-29
US20190192626A1 (en) 2019-06-27
SG11201809086YA (en) 2018-11-29
CA3022497A1 (en) 2017-11-02
WO2017186250A1 (en) 2017-11-02
KR20190003592A (ko) 2019-01-09
RU2018141326A (ru) 2020-05-29
EP3448409A1 (en) 2019-03-06
CN109414474A (zh) 2019-03-01
CN109414474B (zh) 2024-07-02
KR102465341B1 (ko) 2022-11-09
EP3448409C0 (en) 2025-12-03
RU2740913C2 (ru) 2021-01-21
BR112018071972A2 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
ES2871117T3 (es) Procedimientos para modular la microbiota intestinal
ES3057685T3 (en) Treatment of liver, biliary tract and pancreatic disorders with defensins
ES2915851T3 (es) Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
ES2688367T3 (es) Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
ES2882520T3 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina y su uso
ES2748158T3 (es) Formulación líquida de conjugado de proteínas que comprende la oxintomodulina y un fragmento de inmunoglobulina
ES2802099T3 (es) Una composición para el tratamiento de la diabetes que comprende un análogo de oxintomodulina
ES3023833T3 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
BRPI0610091B1 (pt) Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
ES2976562T3 (es) Derivado del glucagón
PT2906595T (pt) Derivados de exendina-4 como duplos agonistas de glp1/glucagon
CN103732618A (zh) 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
BR112020021245A2 (pt) derivado de um análogo de peptídeo semelhante a glucagon 1, métodos para preparar o derivado, para prevenir e/ou tratar diabetes ou complicações diabéticas e para reduzir glicose no sangue, aumentar tolerância à glicose, reduzir apoptose de célula beta de ilhota, intensificar função de célula beta de ilhota, aumentar número de célula beta de ilhota e/ou restaurar sensibilidade à glicose de célula beta de ilhota, composição farmacêutica, usos do derivado e do análogo, análogo de peptídeo semelhante a glucagon 1, e, produto.
ES2679520T3 (es) Formulaciones de moléculas del factor de liberación de hormonas del crecimiento (GRF) con estabilidad mejorada
ES2887086T3 (es) Procedimiento para producir yema de huevo con alto contenido de af-16
TW202528338A (zh) 方法
CN102781476A (zh) 改进经口递送的方法
TWI361694B (en) Use of bombesin/gastrin-releasing peptide antagonists for the treatment of sepsis or acute lung injury
BR112021000933A2 (pt) polipeptídeo, composição farmacêutica, método de preparação dela e método de prevenção ou tratamento de doenças
HK40001163B (en) Methods for modulating intestinal microbiota